CRISPR Therapeutics AG — Director's Dealing 2022

Dec 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2022-12-06

Reporting Person: Kulkarni Samarth (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-06	Common Shares	M	58233	$1.81	Acquired	369111	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-06	Stock Option (Right to Buy)	$1.81	M	58233	Disposed	2025-09-10	Common Shares (58233)	Direct

Footnotes

F1: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vested in equal 36 monthly installments thereafter.